Ken Griffin Insulet Corp Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$163.6 - $209.11 $3.73 Million - $4.77 Million	-22,800 Reduced 16.84%	112,600 $19.3 Million
Q4 2023 Feb 14, 2024	SELL	$127.77 - $221.42 $3.92 Million - $6.8 Million	-30,700 Reduced 18.48%	135,400 $29.4 Million
Q3 2023 Nov 14, 2023	BUY	$154.67 - $290.89 $18.4 Million - $34.6 Million	119,100 Added 253.4%	166,100 $26.5 Million
Q2 2023 Aug 14, 2023	SELL	$272.48 - $330.23 $6.19 Million - $7.5 Million	-22,700 Reduced 32.57%	47,000 $13.6 Million
Q1 2023 May 15, 2023	SELL	$276.36 - $326.03 $884,352 - $1.04 Million	-3,200 Reduced 4.39%	69,700 $22.2 Million

Q4 2022 Feb 14, 2023	BUY	$212.22 - $313.46 $4.44 Million - $6.55 Million	20,900 Added 40.19%	72,900 $21.5 Million
Q3 2022 Nov 14, 2022	BUY	$224.6 - $281.45 $3.55 Million - $4.45 Million	15,800 Added 43.65%	52,000 $11.9 Million

614

62.9M

339K

916K

Ticker PODD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 69,403,600
Market Cap $14.3B
Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sel...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.